irAE occurrence has been associated with improved outcomes for patients treated with anti-PD-(L)1 or anti-CTLA-4 ICI primarily in the context of melanoma (15–19), non-small cell lung cancer (NSCLC) (13, 20, 21), and urothelial cancer (19). Here, CTLA4 is linked to melanoma.